ArticleCell communication and signaling : CCS2026
From cell lines to the clinic: identifying a urinary BlCa-EV signature through comparative proteomics of bladder cancer lysates and extracellular vesicles.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThere is an urgent need for the development of innovative diagnostic and therapeutic strategies in bladder cancer (BlCa) management, due to its significant incidence, mortality, and morbidity. Extracellular vesicles (EVs) constitute promising candidates as biomarkers, as their cargo is highly protected from degradation, and they can be isolated non-invasively from urine. Furthermore, they play a pivotal role in intercellular communication that drives disease progression, making them suitable candidates for tailored therapy approaches.
methodsWe employed high-throughput mass-spectrometry to perform a comprehensive proteomic analysis of cell lysates and matched EVs. EVs were isolated from six distinct human BlCa cell lines, representatives of the complete disease spectrum, to identify a BlCa-EV associated signature. The translational ability of this signature was analyzed in urinary EV (uEV) samples from BlCa patients and healthy controls.
resultsThis study established a new lysate-to-EV signature that is common to all malignant cell lines. Afterwards, this profile was analyzed in BlCa uEVs, identifying a robust and novel 13-protein BlCa-enriched signature, which includes ITGA2, ITGA6, SCRIB, and TFRC.
conclusionWe unveiled a novel, EV-derived protein signature that has potential to be further applied for future functional studies, non-invasive diagnostic assays and targeted therapeutic interventions against BlCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.